17/08/2026
Biomarkers and Immunotherapy in Endometrial Cancer👇
✅Endometrial cancer (EC) can be classified into four major molecular subtypes using the ProMisE classification: mismatch repair-deficient (MMRd), POLE-mutated (POLEmut), p53-abnormal (p53abn), and no specific molecular profile (NSMP).
✅The tumor microenvironment (TME) contains a complex network of immune cells, including T cells, regulatory T cells, NK cells, macrophages, dendritic cells, and monocytes, all of which can influence tumor progression and response to treatment.
✅Immune checkpoint inhibitors (ICIs) targeting pathways such as PD-1 and CTLA-4 have become important components of immunotherapeutic strategies for selected patients with endometrial cancer.
✅Emerging biomarkers may help predict treatment response. These include tumor mutational burden (TMB), FANCE, LRP2 mutations, and other molecular and immune-related features.
✅Combination strategies are also being investigated, including immunotherapy combined with anti-angiogenic agents, chemotherapy, and cancer-cell-targeted approaches, with the goal of improving therapeutic responses.
✅Another important challenge is immunotherapy resistance. Understanding the mechanisms behind resistance and developing strategies to overcome them could expand the benefits of immunotherapy to more patients.
✅Machine learning is also emerging as a tool for biomarker discovery, immune-response prediction, and prognostic stratification, potentially helping clinicians identify patients who are more likely to benefit from specific treatments.
💡 Zhao L, Li X, Jing Y, Tang L, Lin F, Zhang Y, Tang Y, Chen C, Yang J, Liu X and Chen J (2025) Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications. Front. Immunol. 16:1684549. doi: 10.3389/fimmu.2025.1684549